Game-Changing Advancements Are Transforming The Obesity Drug Market
Growing market for obesity drugs expected to reach $100B by 2030
Potential Game Changers in Obesity Drug Market
While injectable GIP/GLP-1 have garnered attention, leading companies acknowledge imperative of adopting novel drug development approaches.
differentiator. Source: BioSpace; Medical Marketing and Media (MM+M)
Major recent deals and acquisitions
NovoNordisk is at the forefront with 6 upcoming launches in the upcoming 5 years. EliLilly is making waves too, advancing the development of combinations and oral drugs. Other big pharma like AstraZeneca and Roche are recognizing the potential of the obesity drug market with deals and collaborations.
While injectable GIP/GLP-1 has garnered attention, leading companies acknowledge the imperative of adopting novel drug development approaches.
Related Insights & Outlooks
Q3-2024 Top Pharma Earnings Results
•
November 18, 2024
From breakthrough therapies to strategic market maneuvers, here’s how the Top 15 Pharma Companies navigated the quarter’s challenges and opportunities.
Q2-2024 Top Pharma Earnings Results
•
August 14, 2024
The pharmaceutical industry showed impressive performance in Q2 2024, with a notable focus on innovation and expansion.
.avif)